Abstract

Circular RNAs (circRNAs) play critical regulatory roles in cancer biological processes. Nevertheless, the contributions and underlying mechanisms of circRNAs to pancreatic ductal adenocarcinoma (PDAC) remain largely unexplored. Dysregulated circRNAs between cancerous tissues and matched adjacent normal tissues were identified by circRNA microarray in PDAC. The biological effect of hsa_circ_007367 both in vitro and in vivo was demonstrated by gain- and loss-of-function experiments. Further, dual-luciferase reporter and RNA pull-down assays were performed to confirm the interaction among hsa_circ_007367, miR-6820-3p, and Yes-associated protein 1 (YAP1). The expression of hsa_circ_007367 and YAP1 were detected by in situ hybridization (ISH) and immunohistochemistry (IHC) using tissue microarray (TMA) in 128 PDAC samples. We first identified that a novel circRNA, hsa_circ_0007367, was markedly upregulated in PDAC tissues and cells. Functionally, in vivo and in vitro data indicated that hsa_circ_0007367 promotes the proliferation and metastasis of PDAC. Mechanistically, we confirmed that hsa_circ_0007367 could facilitate the expression of YAP1, a well-known oncogene, by sponging miR-6820-3p, which function as a tumor suppresser in PDAC cells. The results of ISH and IHC demonstrated that hsa_circ_0007367 and YAP1 were upregulated in PDAC tissues. Furthermore, clinical data showed that higher hsa_circ_0007367 expression was correlated with advanced histological grade and lymph node metastasis in PDAC patients. In conclusion, our findings reveal that hsa_circ_0007367 acts as an oncogene via modulating miR-6820-3p/YAP1 axis to promote the progression of PDAC, and suggest that hsa_circ_0007367 may serve as a potential therapeutic target for treatment of PDAC.

Details

Title
Circular RNA hsa_circ_0007367 promotes the progression of pancreatic ductal adenocarcinoma by sponging miR-6820-3p and upregulating YAP1 expression
Author
Zhang, Haocheng 1 ; Ma, Xiaolei 2 ; Wang, Luning 2 ; Li, Xinyu 2 ; Feng, Di 3 ; Liu, Meiming 2 ; Li, Jiayang 2 ; Cheng, Mengxing 2 ; Song, Na 2 ; Yang, Xinxia 2 ; Ba, Lina 2 ; Lei, Yating 2 ; Zhang, Ruipu 4 ; Zhu, Yunxiao 3 ; Xu, Wenxiao 4 ; Qiao, Guofen 2   VIAFID ORCID Logo 

 Harbin Medical University, Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin, China (GRID:grid.410736.7) (ISNI:0000 0001 2204 9268); the Sixth Affiliated Hospital of Harbin Medical University, Department of Pharmacy, Harbin, China (GRID:grid.410736.7) (ISNI:0000 0001 2204 9268) 
 Harbin Medical University, Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin, China (GRID:grid.410736.7) (ISNI:0000 0001 2204 9268) 
 Harbin Medical University Cancer Hospital, Department of Pathology, Harbin, China (GRID:grid.412651.5) (ISNI:0000 0004 1808 3502) 
 Harbin Medical University, Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin, China (GRID:grid.410736.7) (ISNI:0000 0001 2204 9268); the Second Affiliated Hospital of Harbin Medical University, Department of Orthopedics, Harbin, China (GRID:grid.412463.6) (ISNI:0000 0004 1762 6325) 
Publication year
2022
Publication date
Aug 2022
Publisher
Springer Nature B.V.
e-ISSN
20414889
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2706500496
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.